RT Journal Article
SR Electronic
T1 An overview of global monitoring systems for the side effects and adverse events associated with medicinal cannabis use: A scoping review using a systematic approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.03.24302171
DO 10.1101/2024.02.03.24302171
A1 Wang, Rebecca Qi
A1 Bonomo, Yvonne Ann
A1 Hallinan, Christine Mary
YR 2024
UL http://medrxiv.org/content/early/2024/02/04/2024.02.03.24302171.abstract
AB The use of cannabis-based medicines (CBM) as a therapeutic has grown exponentially over the last 5 years in Australia. Prior to this increase, there was significant legislative resistance to the use of CBM for clinical trials, hence pre-clinical data is limited. Safety monitoring systems for CBM are not structured and do not fit easily into the workflow of busy health professionals. Hence, post-marketing surveillance of CBM is patchy. CBM are available in many countries globally and face similar issues in relation to pharmacovigilance. The objective of this review is to answer the following question: What are the systems in place internationally to monitor side effects and adverse events of cannabis use as a medicine?We used the PICO framework to develop keyword elements, which guided two search queries. Each query contained a different combination of keywords to increase sensitivity and specificity of the search. Both queries were entered into Embase and Scopus for retrieval of quality relevant peer-reviewed literature. Only the second search query, was used for the grey literature. Fifty-four full text articles were included in the review, thirty-nine were from the peer-reviewed search, eight were from the grey literature search, and seven were from citations of relevant texts.Our search yielded two main forms of monitoring systems: databases and registries, with databases often created by regulatory authorities. There was great variability within these systems, differing in methods of causality assessment, level of detail collected, terminology, and affiliations. Only one monitoring system captured in our search obligated reporting from patients.VigiBase remains the largest form of centralised monitoring, receiving case reports internationally. Regardless of the scope of VigiBase, there remains heterogeneity of data within the system. As such, our study reaffirms a greater need for a centralised, consistent, and accessible system for the post-marketing surveillance of side effects and adverse events associated with usage of CBM.What is already known on this topicReal-world data is essential for monitoring the side effects and adverse events associated with the use of cannabis-based medicines, given the limited availability of clinical trials, increasing clinical demand, and rising accessibility to unregulated cannabis-based products.In some countries, registries and databases exist for post-marketing surveillance of side effects and adverse events at a national level.What this review addsA summary of the current landscape of monitoring systems at an international level, and interactions, and reporting hierarchies that exist between systems.An analysis of the content, specificity, and scope of each monitoring system, including an analysis of the reporting type, be it mandatory or spontaneous.How this study might affect research, practice, or policy (summarise implications)A robust and standardised system is required for ongoing post-marketing surveillance of the side effects and adverse events associated with usage of cannabis-based medicine.Development of a system that is both accessible and well-integrated into healthcare professional clinical workflow is needed.Future practice and policy guided by this research can establish a standardised approach for collecting safety data that aligns with the rapid adoption of cannabis-based medicines in clinical settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Health and Medical Research Council (NHMRC) through the Centre of Research Excellence scheme (NHMRC CRE APP1135054)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript CBMCannabis-based medicinesTGATherapeutic Goods’ AdministrationCBDCannabidiolTHCDelta-9-tetrahydrocannabinolMSMultiple sclerosisRARheumatoid arthritis Irritable Bowel syndrome: IBSFAERSFDA Adverse events reporting systemCVARCanada Vigilance Adverse Reaction Online DatabaseEDSADREudravigilance European Database of Suspected Adverse Drug Reaction ReportsDAENTGA Database of Adverse event NotificationsUKMCRUK Medical Cannabis RegistryAIFAItalian Medicines Agency